“…A potential therapeutic strategy for BFCN degeneration with translational potential is perinatal maternal choline supplementation (MCS). In the developing fetus, choline is involved in effective neural tube closure, organogenesis, central nervous system cell membrane synthesis, and gene expression related to altering DNA methylation (Zeisel and Blusztajn, 1994;Blusztajn et al, 1998;Zeisel, 2000;Fisher et al, 2001;Cooney et al, 2002;Niculescu et al, 2004;Wurtman et al, 2009;Blusztajn et al, 2017). When supplemented in utero and in early development, choline has both immediate and long-term beneficial effects in healthy disomic rats and mice (Meck et al, 1988;1989;Loy et al, 1991;Holler et al, 1996;Meck and Williams, 1997;1999;Pyapali et al, 1998;Tees, 1999;Sandstrom et al, 2002;Li et al, 2004;Mellott et al, 2004) and in rodent models of prenatal ethanol exposure, Rett syndrome, and status epilepticus (Holmes et al, 2002;Nag and Berger-Sweeney, 2007;Thomas et al, 2007;Nag et al, 2008;Ward et al, 2008;Thomas et al, 2009).…”